Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report

被引：0

作者：

Ogawa, Shoko ^{[1
]}

Konishi, Ken-ichiro ^{[1
]}

Tanaka, Kiyoshi ^{[2
]}

Takayasu, Hajime ^{[1
]}

Uematsu, Yoshimasa ^{[1
]}

Ito, Takashi ^{[3
]}

Takahashi, Hiroyuki ^{[4
]}

Kumamoto, Yusuke ^{[1
]}

机构：

[1] Kitasato Univ, Sch Med, Dept Gen Pediat & Hepatobiliary Pancreat Surg, Sagamihara, Kanagawa, Japan

[2] Kitasato Univ, Sch Med, Res & Dev Ctr New Med Frontiers, Dept Adv Med,Div Pediat Surg, Sagamihara, Kanagawa, Japan

[3] Kitasato Univ, Sch Med, Dept Pathol, Sagamihara, Kanagawa, Japan

[4] Kitasato Univ, Sch Allied Hlth Sci, Dept Pathol, Sagamihara, Kanagawa, Japan

来源：

FRONTIERS IN PEDIATRICS | 2024年 / 12卷

关键词：

glucagon-like peptide-2 analog; immune effect; short bowel syndrome; eosinophilic gastrointestinal diseases; teduglutide; COWS MILK ALLERGY; ANTIINFLAMMATORY ACTIONS; INFLAMMATION; PATHWAYS; BARRIER;

D O I：

10.3389/fped.2024.1457824

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

We successfully treated a 4-year-old girl with short bowel syndrome and eosinophilic enterocolitis with teduglutide, a glucagon-like peptide-2 analog. Her eosinophilic enterocolitis was cured without relapse, and we were able to increase enteral nutrition. We found that teduglutide had an anti-inflammatory effect in this patient with eosinophilic gastrointestinal disease associated with short bowel syndrome. This report is the first to describe use of teduglutide in the treatment of eosinophilic gastrointestinal disease.

引用

页数：5

共 50 条

[1] Teduglutide: A novel recombinant analog of human glucagon-like peptide-2 for short bowel syndrome
Canada, Todd
FORMULARY, 2012, 47 (09) : 314 - 318
[2] Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome
Yazbeck, Roger
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (06) : 798 - 809
[3] Glucagon-like peptide-2
Estall, Jennifer L.
Drucker, Daniel J.
ANNUAL REVIEW OF NUTRITION, 2006, 26 : 391 - 411
[4] Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, LL
Drucker, DJ
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) : 531 - 554
[5] The Glucagon-Like Peptide 2 Analog Teduglutide Reversibly Associates to Form Pentamers
Philo, John S.
Sydor, Wasyl
Arakawa, Tsutomu
JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (01) : 775 - 784
[6] The effect of glucagon-like peptide-1 and glucagon-like peptide-2 on microcirculation: A systematic review
Nerup, Nikolaj
Ambrus, Rikard
Lindhe, Joanna
Achiam, Michael P.
Jeppesen, Palle B.
Svendsen, Lars B.
MICROCIRCULATION, 2019, 26 (03)
[7] Glucagon-like peptide-2 analog and inflammatory state in obese mice
Sara Baldassano
Antonella Amato
Simona Terzo
Gaetano Felice Caldara
Laura Lentini
Flavia Mulè
Endocrine, 2020, 68 : 695 - 698
[8] Glucagon-like peptide-2 analog and inflammatory state in obese mice
Baldassano, Sara
Amato, Antonella
Terzo, Simona
Caldara, Gaetano Felice
Lentini, Laura
Mule, Flavia
ENDOCRINE, 2020, 68 (03) : 695 - 698
[9] Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, Thomas A.
Osto, Elena
CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (03) : 257 - 263
[10] The dimerization of glucagon-like peptide-2 MIMETIBODY™ is linked to leucine-17 in the glucagon-like peptide-2 region
E. Baker, Audrey
Sague, Sarah
Grygiel, Tami L. R.
Schmidt, Albert
Rogers, Alison
Jiang, Haiyan
Kruszynski, Marian
Nesspor, Tom
JOURNAL OF MOLECULAR RECOGNITION, 2012, 25 (03) : 155 - 164

← 1 2 3 4 5 →